Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulcrum Therapeutics, Inc. (Nasdaq: FULC) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulcrum is a clinical-stage biopharmaceutical company focused on small-molecule modulation of gene expression for genetically defined rare diseases, with its lead program pociredir in sickle cell disease.
Through this page, readers can access current reports on Form 8-K in which Fulcrum reports material events. Recent 8-K filings describe quarterly financial results, initial and updated data from the Phase 1b PIONEER trial of pociredir in sickle cell disease, and an underwriting agreement for a public offering of common stock and pre-funded warrants. Other 8-Ks cover items such as updated corporate presentations, annual meeting voting results, and stockholder advisory votes on executive compensation.
Fulcrum’s filings also reference its shelf registration statement on Form S-3, under which it has conducted underwritten public offerings, and detail the terms of pre-funded warrants, lock-up agreements, and related underwriting arrangements. As a Nasdaq-listed issuer, Fulcrum files periodic reports and maintains registration of its common stock under Section 12(b) of the Exchange Act.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Users can quickly see what each 8-K, registration statement, or related exhibit means for topics such as clinical trial updates, capital-raising transactions, and governance matters. Real-time ingestion from EDGAR helps ensure that new Fulcrum filings, including future annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 when available, are surfaced promptly with concise AI insights to support further research.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 4,589,000 shares of Fulcrum Therapeutics common stock, representing 8.50% of the class based on 53,979,306 shares outstanding. The shares are held directly by Adage Capital Partners, L.P., with Adage acting as investment manager and Messrs. Atchinson and Gross identified as managing members of the related entities.
The filing shows no sole voting or dispositive power; all voting and disposition power is reported as shared. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Fulcrum Therapeutics (NASDAQ:FULC) filed a Form 8-K reporting the results of its 26 June 2025 annual stockholder meeting.
- Shareholders elected Katina Dorton, Robert Gould and Kate Haviland as Class III directors for terms ending in 2028.
- The non-binding say-on-pay proposal passed with 46.1 million votes for, 0.11 million against and 8.3 thousand abstentions.
- Investors recommended an annual frequency for future say-on-pay votes (44.9 million votes for one year).
- Ernst & Young LLP was ratified as independent auditor for fiscal 2025 with 49.5 million votes for and no broker non-votes.
No other material corporate actions or operational changes were disclosed.